Pharmacokinetics, Efficacy, Gametocyte Carriage, Birth Outcomes Following Sulfadoxine-pyrimethamine Intermittent Presumptive Treatment in Pregnant Women

Overview

The main purpose of this study is to compare the drug levels of sulfadoxine-pyrimethamine found when given to pregnant women for the prevention of malaria to those found in pregnant women given the same drug with artesunate for the treatment of malaria, and also with those drug levels found in non-pregnant women in other malaria treatment studies.

Full Title of Study: “An Open-label in Vivo Drug Study to Evaluate the Pharmacokinetics, Therapeutic Efficacy, Gametocyte Carriage and Birth Outcomes Following Sulfadoxine-pyrimethamine Intermittent Presumptive Treatment (SP IPT) in Pregnant Women”

Study Type

  • Study Type: Interventional
  • Study Design
    • Allocation: N/A
    • Intervention Model: Single Group Assignment
    • Primary Purpose: Prevention
    • Masking: None (Open Label)
  • Study Primary Completion Date: February 2008

Detailed Description

Pregnancy increases the risk of malaria progression and complications with up to a 10-fold increase in the malaria case fatality rate in areas of low transmission. Sulfadoxine-pyrimethamine (SP) is used widely in Africa for the systematic intermittent presumptive, or preventive, treatment (IPTp) during the second and third trimester of pregnancy and a national program of IPTp with SP has been implemented recently in Mozambique. There is evidence that the kinetics of several other antimalarial drugs are altered in pregnancy to the extent that doses are not adequate in pregnancy, however no published study has included a pharmacokinetic component to confirm that standard doses of SP are optimal in this vulnerable patient group. This study therefore creates the opportunity to study whether the pharmacokinetic properties of SP are altered by physiological changes that occur during pregnancy.

Interventions

  • Drug: sulfadoxine-pyrimethamine

Arms, Groups and Cohorts

  • Experimental: SP plus artesunate
    • SP (Fansidar®, Roche South Africa) at a dose of 25/1.25mg/kg of sulfadoxine/pyrimethamine respectively on day 0 only, and artesunate (Arsumax®, Sanofi-Aventis, South Africa) at a dose of 4mg/kg on days 0, 1, and 2

Clinical Trial Outcome Measures

Primary Measures

  • Pharmacokinetic parameters by measurement of whole blood levels of sulfadoxine and pyrimethamine and plasma levels of artesunate to determine Cmax, Tmax, AUC, half life, volume of distribution and clearance
    • Time Frame: 0 hours (pre treatment) and repeated on day 0 or 1 at 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12 and 24 hours, and days 2, 3, 7, 14, 21, 28 and 42

Secondary Measures

  • Correlation of treatment outcome and gametocyte carriage with pharmacokinetic parameters and pregnancy status
    • Time Frame: 0 hours (pre treatment) and repeated on day 0 or 1 at 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12 and 24 hours, and days 2, 3, 7, 14, 21, 28 and 42 , and time of birth outcome
  • Correlation of frequency of DHFR mutations at codons 436, 437, 540 and 581 in maternal and placental samples with treatment outcomes
    • Time Frame: Day 42 (or day of withdrawal)
  • Birth outcomes in terms of major congenital abnormalities, spontaneous abortions, still births and neonatal deaths, gestational age and birth weight, placental weight, newborn head circumference, arm circumference and neurological development
    • Time Frame: Day of birth outcome
  • Risk of harm by describing all adverse events and their causality assessments and changes in full blood count, glucose, bilirubin, creatinine, urea and ALT
    • Time Frame: Days 3, 7, 14, 21, 28 and every 2 weeks thereafter until birth (for a minimum of 42 days) or withdrawal visit
  • Capacity building by describing the training and development of study teams and their subsequent skills attained
    • Time Frame: Duration of trial

Participating in This Clinical Trial

Inclusion Criteria

  • Pregnant female, older than 18 years, > 35kg. – Gestational age > 16 weeks (fundal height > 16cm) and below 36 weeks gestation. – Documented informed consent. – Lives close enough to the study site for reliable follow up and is willing to attend ANC and follow-up visits regularly. Exclusion Criteria:

  • Diagnoses of uncomplicated acute P. falciparum malaria parasitaemia – Has received anti-malarial treatment in the past 7 days and/or sulfadoxine-pyrimethamine in the past 28 days. – Known hepatic or renal impairment – Has received chloramphenicol, cotrimoxazole or tetracyclines (including doxycycline) in the past 7 days or is likely to require these during the study period. – History of G6PD deficiency. – Has a history of allergy to any of the study drugs (including other sulphonamides e.g. cotrimoxazole). – Serious underlying disease that in the opinion of the clinic team and/or Principal Investigator would make the patient unsuitable for the study in terms of their safety or study analysis. – Imminent delivery expected. – Prior inclusion in this study.

Gender Eligibility: Female

Minimum Age: 18 Years

Maximum Age: N/A

Are Healthy Volunteers Accepted: No

Investigator Details

  • Lead Sponsor
    • Professor Karen I Barnes
  • Collaborator
    • Global Fund
  • Provider of Information About this Clinical Study
    • Sponsor-Investigator: Professor Karen I Barnes, Professor, Clinical Pharmacology – University of Cape Town
  • Overall Official(s)
    • Karen I Barnes, MBChB, Principal Investigator, University of Cape Town

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.